TL;DR
This paper introduces DS-7011a, a novel humanized antibody designed to specifically inhibit Toll-like Receptor 7 (TLR7). By demonstrating that TLR7 plays a more significant role than TLR8 in human Systemic Lupus Erythematosus (SLE) and showing DS-7011a's efficacy in preclinical models, the research presents a promising new therapeutic avenue for SLE patients.
What Problem Does This Paper Address?
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease where the body's immune system mistakenly attacks its own tissues. A key player in this process is Toll-like Receptor 7 (TLR7), an endosomal sensor that recognizes single-stranded RNA (ssRNA). While TLR7's involvement in SLE is established in animal models, its specific role in humans, especially in comparison to the related TLR8 (which also senses ssRNA), has been less clear. Existing therapeutic strategies often involve broad immunosuppression, which can lead to significant side effects and increased infection risk. The paper aims to clarify TLR7's specific contribution to human SLE and develop a targeted therapy to mitigate its effects without the broad immunosuppression associated with current treatments.
Methods
The researchers employed a multi-pronged approach:
- Gene Signature Analysis: They analyzed public transcriptomic datasets to compare the gene signature scores (GSs) of TLR7 and TLR8 in SLE patients versus healthy individuals. This helped quantify the relative involvement of each receptor in the disease.
- Monoclonal Antibody (mAb) Development:
- Generation of Inhibitory mAbs: They immunized mice with human TLR7 (HuTLR7) and HuTLR7-expressing cells to generate anti-HuTLR7 mAbs.
- Screening and Selection: These mAbs were screened for their ability to bind HuTLR7 and, crucially, to inhibit TLR7-dependent NF-κB activation in a reporter cell line (Ramos cells).
- Epitope Mapping: Chimeric human-mouse TLR7 proteins were used to pinpoint the specific region on TLR7 where the inhibitory antibodies bind.
- Humanization: A lead inhibitory clone (S1) was selected and humanized to create DS-7011a, a human IgG1 antibody with modifications to reduce effector function.
- In Vitro Assays:
- Cell Staining and Flow Cytometry: Used to confirm antibody binding to TLR7 and to assess TLR7 and TLR8 expression on various immune cell types (pDCs, B cells, cDCs, monocytes).
- Cytokine Production Assays (ELISA, AlphaLISA): Measured the production of inflammatory cytokines (IL-6, IFN-α) by human PBMCs, pDCs, and B cells upon stimulation with TLR7 ligands, both with and without DS-7011a.
- IgG Production Assays: Assessed the impact of DS-7011a on IgG production by human B cells.
- In Vivo Studies:
- Mouse Models: Utilized human TLR7 transgenic mice (HuTLR7-Tg) to evaluate the in vivo efficacy of the anti-TLR7 mAb (clone S1).
- Serum Cytokine Measurement: Measured IL-12p40 levels in the serum of treated mice after TLR7 ligand stimulation.
- Antibody Uptake Assay: Investigated whether DS-7011a is internalized by immune cells in a TLR7-dependent manner using fluorescently labeled antibodies and flow cytometry.
Datasets
- Public Transcriptomic Datasets: Three whole blood transcriptome datasets from SLE patients were obtained from the Gene Expression Omnibus (GEO) database (GSE88884, GSE65391, GSE49454). These datasets were used for gene signature analysis to compare TLR7 and TLR8 expression levels between SLE patients and healthy controls.
Key Insights and Ideas
- TLR7 Dominance in Human SLE: The gene signature analysis strongly suggests that TLR7, not TLR8, is more significantly activated in human SLE across various datasets, races, and disease activity scores. This is a crucial finding that justifies targeting TLR7 specifically.
- Targeted Inhibition is Key: Unlike broad immunosuppressants or dual TLR7/8 antagonists, a specific anti-TLR7 antibody like DS-7011a offers a more precise therapeutic approach, potentially minimizing risks associated with inhibiting TLR8 (e.g., increased susceptibility to certain infections).
- Internalization for Efficacy: The observation that DS-7011a is internalized in a TLR7-dependent manner and accumulates in key immune cells (B cells, pDCs, cDCs, monocytes) is vital. This suggests that the antibody actively engages with its target within the cell, potentially leading to sustained inhibition.
- Epitope Location and Mechanism: The inhibitory antibodies bind to a specific region (276-313) on the extracellular domain of TLR7, which is distant from the ligand-binding site. This hints at a mechanism of action that might involve altering TLR7 conformation or promoting its removal from signaling pathways, rather than directly blocking ligand binding.
Key Results
- Elevated TLR7 GS: TLR7 gene signature scores were consistently and significantly higher in SLE patients compared to healthy controls across multiple datasets. TLR8 GS, while sometimes elevated, showed less consistent or pronounced differences.
- Development of Inhibitory mAbs: Several inhibitory anti-human TLR7 mAbs were generated, with clone S1 showing potent inhibition of TLR7-mediated NF-κB activation.
- DS-7011a Efficacy: The humanized antibody DS-7011a effectively inhibited TLR7-dependent IL-6 and IFN-α production in human PBMCs, as well as IFN-α production in pDCs and IgG production in B cells.
- In Vivo Inhibition: Clone S1 significantly reduced serum IL-12p40 levels in human TLR7 transgenic mice after R848 stimulation, demonstrating in vivo efficacy.
- Cellular Uptake: DS-7011a was internalized by TLR7-expressing cells (B cells, pDCs, cDCs, monocytes) in a TLR7-dependent manner, but not by T cells which lack TLR7 expression.
Limitations and Future Work
- Mechanism of Action: While the epitope is identified, the precise molecular mechanism by which DS-7011a inhibits TLR7 signaling (beyond blocking ligand binding) requires further elucidation. The authors suggest it might involve altered TLR7 distribution or trafficking within the endosomal compartment.
- Species Specificity: While DS-7011a is specific for human TLR7, its binding to monkey TLR7 was noted as advantageous for potential preclinical studies in non-human primates. However, it does not bind to mouse TLR7, necessitating the use of humanized mouse models for in vivo testing.
- Clinical Translation: The paper presents preclinical data. While a Phase 1a study showed DS-7011a to be safe and well-tolerated, further clinical trials (a Phase 1b/2 study in SLE patients is ongoing) are crucial to confirm its therapeutic benefit and long-term safety in humans.
- Infection Risk: Although DS-7011a is designed to be specific for TLR7, the potential for any antibody-based therapy to impact immune responses and infection risk warrants continued monitoring. The authors highlight that dual TLR7/8 inhibition might carry a higher infection risk, implying TLR7-specific inhibition could be safer.
Summary updated